### **Overview** Gujarat Terce Laboratories Ltd. is a well-established Indian pharmaceutical company with nearly four decades of experience in manufacturing and marketing **branded generic pharmaceuticals**. Founded in 1985 and headquartered in **Ahmedabad, Gujarat**, the company is led by **Mr. Aalap Prajapati, Managing Director & CEO**. It has evolved into a focused player in the domestic prescription-driven pharma market, emphasizing brand building, strategic product development, and deep physician engagement. --- ### **Business & Product Portfolio** - **Product Range**: The company markets **134–135 products** across **acute and chronic therapy segments**, organized under **50–52 established brands**, with **8–10 core leading brands** forming the backbone of its revenue stream. - **Therapeutic Focus**: High-growth areas including: - **Paediatrics** - **Gynaecology** - **Orthopaedics** - **General Medicine** - **Respiratory, Gastroenterology, Nutraceuticals, and Ayurvedic Products** - **Revenue Drivers**: - In FY25, the **top 10 high-value "precious products"** contributed **55.99% of total revenue**, with a **year-on-year growth of 6.69%**, driven by targeted marketing and brand equity. - These products cater primarily to **General Practitioners, Paediatricians, and Gynaecologists**, and include brands like **Codimol, oVitfol, eTelflora Z, Rabter DSR**, and **Resplash**. - **Codimol**, a flagship antibiotic, generated **₹7,331.76 crore in revenue in FY24**, underscoring the company’s strength in anti-infectives. - **Segmental Revenue Contributions (FY24)**: - **Antibiotics**: 30.13% - **Respiratory**: 23.32% - **Nutraceuticals**: 12.22% (top 3 brands earned ₹398.83 lakh) - **Gynaecology**: 8.32% - **Gastroenterology**: 6.27% (highlighted as a future growth segment) - **Ayurvedic Products**: ₹90.02 lakh in revenue, with rising traction in the fast-growing herbal market. - **Product Strategy**: - A **focused, not broad**, product rollout approach — launching fewer, targeted products in **underpenetrated therapeutic segments**, generating **₹1.08 crore cumulatively in FY25**. - Strategic discontinuation of low-performing SKUs over the last 5–6 years, optimizing portfolio for **profitability and margin improvement**. - Shift in focus from **acute to chronic therapies** to build stable, recurring revenue; the mix has evolved from 75:25 (acute:chronic) to a target of **70:30**. --- ### **Manufacturing & Strategic Shift** - **Legacy Manufacturing Facility**: - Located in **Chhatral, Gandhinagar, Gujarat** (established 1992), spanning **3,375 sq. meters** and **337,550 sq. ft. (alternate data)**. - WHO-GMP and ISO 9001 certified, with annual capacities of: - **720 million tablets** - **185 million capsules** - However, the facility requires major investment to comply with **Revised Schedule M** standards. - **Strategic Decision (Announced July 2025)**: - Gujarat Terce plans to **sell its Chhatral manufacturing plant** due to limited contribution to overall portfolio and high compliance costs. - **Transition to CDMOs**: All in-house manufactured brands will be shifted to **WHO-GMP-certified Contract Development and Manufacturing Organizations (CDMOs)**. - **Corporate Quality Assurance team** will retain oversight to ensure consistent product quality. - This shift enables the company to **focus on brand building, marketing, and market expansion**, while improving **supply chain resilience and inventory efficiency**. --- ### **Sales, Marketing & Distribution Network** - **Geographic Reach (Nov 2025)**: - Operates in **13 states and 224 districts**, with strong presence in **North, West, and Central India**. - Previously aimed for **pan-India presence by 2025**, but appears to have rationalized operations to focus on high-performing regions. - **Distribution Strength**: - **385 stockists** ensuring consistent product availability across **urban, semi-urban, and rural markets**. - Improved trade terms have enhanced **working capital cycle and cash flow**. - **Sales Force**: - Employs **240+ team members**, including **147–150 medical representatives**. - Engages over **32,700 doctors** and **30,000+ chemists**, with some sources citing **32,706 doctors and 30,074 chemists**. - Focus on **field productivity, performance management, and continuous training** (including a Management Development Program for mid-level leaders). - **Market Optimization (FY25 Initiatives)**: - Exited low-performing regions and **rationalized geographical footprint** based on data-driven analysis. - Implemented **strategic clustering** to improve operational efficiency. - Strengthened collections through **weekly follow-ups** and strict credit terms, reducing debt and interest burden. - Reduced inventory and logistics costs, improving **profitability and cash flow**. --- ### **Financial & Operational Performance** - Strong historical growth: - **FY22**: Acute therapy grew **58.4%** (vs. industry 19.8%); chronic therapy +33.02% (vs. 10.24%). - **9M FY22**: 60–64.67% YoY revenue growth, significantly outperforming the IPM (18.1%). - **Brand Scalability**: - Number of brands generating **₹1 crore+ in annual revenue** increased from **3 in FY21 to 9 by FY22**, with further expansion ongoing. - In FY23, **8 products earned over ₹1 crore each**, led by high performers like **Acolate (₹9+ crore in Gujarat alone)**, and **Tynol, Codimol, Ocef** (₹3+ crore each).